**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 70355

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Neutrophile-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios as prognostic and response biomarkers for resectable locally advanced gastric cancer**

Tomás TC *et al*. Blood ratios as biomarkers in LAGC

Tiago Cruz Tomás, Inês Eiriz, Marina Vitorino, Rodrigo Vicente, João Gramaça, Alicia Guadalupe Oliveira, Paulo Luz, Mafalda Baleiras, Ana Sofia Spencer, Luísa Leal Costa, Patrícia Liu, Joana Mendonça, Magno Dinis, Teresa Padrão, Marisol Correia, Gonçalo Atalaia, Michelle Silva, Teresa Fiúza

**Tiago Cruz Tomás, Inês Eiriz, Marina Vitorino, Rodrigo Vicente, Gonçalo Atalaia, Michelle Silva, Teresa Fiúza,** Department of Medical Oncology, Hospital Professor Doutor Fernando Fonseca EPE, Amadora 2720-276, Portugal

**João Gramaça,** Department of Medical Oncology, Centro Hospitalar Barreiro-Montijo EPE, Barreiro 2830-003, Portugal

**Alicia Guadalupe Oliveira,** Department of Medical Oncology, Hospital do Espírito Santo de Évora EPE, Évora 7000-811, Portugal

**Paulo Luz,** Department of Medical Oncology, Centro Hospitalar Universitário do Algarve EPE, Algarve 8000-386, Portugal

**Mafalda Baleiras,** Department of Medical Oncology, Hospital São Francisco Xavier, Centro Hospitalar Lisboa Ocidental EPE, Lisboa 1449-005, Portugal

**Ana Sofia Spencer,** Department of Medical Oncology, Hospital Santo António dos Capuchos, Centro Hospital Lisboa Central EPE, Lisboa 1169-050, Portugal

**Luísa Leal Costa,** Department of Medical Oncology, Hospital Beatriz Ângelo, Loures 2674-514, Portugal

**Patrícia Liu,** Department of Medical Oncology, Centro Hospitalar de Trás-os-Montes e Alto Douro EPE, Vila Real 5000-508, Portugal

**Joana Mendonça,** Department of Medical Oncology, Hospital da Senhora da Oliveira EPE, Guimarães 4835-044, Portugal

**Magno Dinis,** Department of Medical Oncology, Hospital Garcia de Orta EPE, Almada 2805-267, Portugal

**Teresa Padrão,** Department of Medical Oncology, Hospital da Luz, Lisboa 1500-650, Portugal

**Marisol Correia,** Department of Medical Oncology, Hospital Distrital de Santarém EPE, Santarém 2005-177, Portugal

**Author contributions:** Tomás TC designed and conducted the research, formally processed the statistical data, and wrote the paper; Vitorino M, Vicente R, Gramaça J, Oliveira AG, Luz P, Spencer AS, Eiriz I, Liu P, Mendonça J, Costa LL, Baleiras M, Dinis M, Correia M, and Padrão T performed the investigation and data collection; Atalaia G, Silva M, and Fiúza T supervised and validated the report.

**Corresponding author: Tiago Cruz Tomás, MD, Doctor,** Department of Medical Oncology, Hospital Professor Doutor Fernando Fonseca EPE, IC 19, Amadora 2720-276, Portugal. tiago.tomas@campus.ul.pt

**Received:** August 2, 2021

**Revised:** September 19, 2021

**Accepted:** June 23, 2022

**Published online:** July 15, 2022

**Abstract**

BACKGROUND

Perioperative fluorouracil plus leucovorin, oxaliplatin, and docetaxel (FLOT) improves prognosis in locally advanced gastric cancer (LAGC). Neutrophil-to-lymphocyte (NLR), lymphocyte-to-monocyte (LMR), and platelet-to-lymphocyte (PLR) ratios are prognostic biomarkers but not predictive factors.

AIM

To assess blood ratios’ (NLR, LMR and PLR) potential predictive response to FLOT and survival outcomes in resectable LAGC patients.

METHODS

This was a multicentric retrospective study investigating the clinical potential of NLR, LMR, and PLR in resectable LAGC patients, treated with at least one preoperative FLOT cycle, from 12 Portuguese hospitals. Means were compared through non-parametric Mann-Whitney tests. Receiver operating characteristic curve analysis defined the cut-off values as: High PLR > 141 for progression and > 144 for mortality; high LMR > 3.56 for T stage regression (TSR). Poisson and Cox regression models the calculated relative risks/hazard ratios, using NLR, pathologic complete response, TSR, and tumor regression grade (TRG) as independent variables, and overall survival (OS) as the dependent variable.

RESULTS

This study included 295 patients (mean age, 63.7 years; 59.7% males). NLR was correlated with survival time (*r* = 0.143, *P* = 0.014). PLR was associated with systemic progression during FLOT (*P* = 0.022) and mortality (*P* = 0.013), with high PLR patients having a 2.2-times higher risk of progression [95% confidence interval (CI): 0.89-5.26] and 1.5-times higher risk of mortality (95%CI: 0.92-2.55). LMR was associated with TSR, and high LMR patients had a 1.4-times higher risk of achieving TSR (95%CI: 1.01-1.99). OS benefit was found with TSR (*P* = 0.015) and partial/complete TRG (*P* < 0.001). Patients without TSR and with no evidence of pathological response had 2.1-times (95%CI: 1.14-3.96) and 2.8-times (95%CI: 1.6-5) higher risk of death.

CONCLUSION

Higher NLR is correlated with longer survival time. High LMR patients have a higher risk of decreasing T stage, whereas high PLR patients have higher odds of progressing under FLOT and dying. Patients with TSR and a pathological response have better OS and lower risk of dying.

**Key Words:** Gastric cancer; Perioperative fluorouracil plus leucovorin, oxaliplatin, and docetaxel; Neutrophil-to-lymphocyte; Lymphocyte-to-monocyte; Platelet-to-lymphocyte; Tumor regression grade

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Tomás TC, Eiriz I, Vitorino M, Vicente R, Gramaça J, Oliveira AG, Luz P, Baleiras M, Spencer AS, Costa LL, Liu P, Mendonça J, Dinis M, Padrão T, Correia M, Atalaia G, Silva M, Fiúza T. Neutrophile-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios as prognostic and response biomarkers for resectable locally advanced gastric cancer. *World J Gastrointest Oncol* 2022; 14(7): 1307-1323

**URL:** https://www.wjgnet.com/1948-5204/full/v14/i7/1307.htm

**DOI:** https://dx.doi.org/10.4251/wjgo.v14.i7.1307

**Core Tip:** Fluorouracil plus leucovorin, oxaliplatin, and docetaxel (FLOT) perioperative regimen has become the standard of care for resectable locally advanced gastric cancer, but there is a need for prognostic and predictive biomarkers. Neutrophil-to-lymphocyte (NLR), lymphocyte-to-monocyte (LMR), and platelet-to-lymphocyte (PLR) ratios are useful in solid tumors. We performed exploratory analyses regarding pathological response prediction and survival outcomes. NLR is weakly correlated with overall survival, high LMR patients have higher risk of T stage regression, high PLR patients have higher odds of progressing under FLOT and higher risk of mortality, and patients without T stage or pathological regression have higher risk of dying.

**INTRODUCTION**

Locally advanced gastric cancer (LAGC) are common gastrointestinal malignancies and are the third leading cause of cancer-related mortality worldwide[1]. Patients with stage IIC and IV gastric cancer have 5-year survival rates of 20.2% and 8.8%, respectively, with most patients diagnosed in the advanced stage due to the absence of signs and symptoms in early-stage disease[2]. Recent developments in chemotherapy (CT) have improved prognosis, even in patients with advanced gastric cancer. There has been a focus on neoadjuvant CT and, despite lacking prognostic and treatment response biomarkers, fluorouracil plus leucovorin, oxaliplatin, and docetaxel (FLOT) perioperative CT has led to improved prognosis in patients with LAGC[3-6]. Available evidence suggests that a favorable histopathological response to treatment may be a useful positive predictive marker in LAGC. Nonetheless, tumor response and prognosis are still difficult to predict before treatment initiation, making potential biomarkers crucial to predict patient prognosis and individualize treatment and follow-up. Many serum biomarkers for early and advanced gastric cancer have been reported: Carcinoembryonic antigen is a frequently used biomarker, as well as carbohydrate antigen 19-9 (CA 19-9), CA 72-4, CA 125, and alpha-fetoprotein, which are also helpful for prognosis and monitoring gastric cancer recurrence[7-9]. However, these biomarkers do not predict responses and survival outcomes because of their limited specificity and sensitivity in LAGC. Although many other serum biomarkers are under investigation (*e.g.,* small noncoding microRNAs; fibroblast growth factor 2 amplification; e-cadherin, phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha, and phosphatase and tensin homolog mutations; mesenchymal epithelial transition gene amplification/overexpression; tumor protein p53 mutation; microsatellite instability), their cost-effectiveness ratio is also high, making them expensive to routinely use in clinical practice[10]. Recently, there has been an effort to validate blood ratios [neutrophil-to-lymphocyte (NLR), lymphocyte-to-monocyte (LMR), and platelet-to-lymphocyte (PLR)] as possible biomarkers, as they are routinely analyzed, cheap, and have known pathophysiological mechanisms associated with cancer development. Inflammation impacts carcinogenesis including tumor initiation, promotion, and metastization of solid and hematological malignancies. Blood immune and inflammatory cells (neutrophils, lymphocytes, platelets, and monocytes), as well as cytokines, play important roles in the tumor microenvironment, invasion, and metastization and are potential biomarkers worth being explored in the context of LAGC[11-14].

Lymphocytes seem to reflect the systemic inflammatory status, and some parameters using these cells predict survival outcomes in cancer patients[15-19]. With lymphocytes playing an important role in cancer immune monitoring and prevention, it appears that a pro-inflammatory microenvironment leads to impaired T-cell responses, mediated by cytokines, compromising cell-mediated immunity[20]. Depending on the inflammatory cytokine mediating the environment, neutrophils may exert either antitumoral or protumoral activities[21]. Under acute inflammatory stimulus, activated neutrophils can undertake antitumoral activity, while under chronic inflammation, these neutrophiles can induce a tumor growth and metastization process. Cytokines such as interleukin-6, which is elevated in gastric cancer patients, can induce protumoral neutrophil activity[22]. This behavior might explain why there is a correlation between neutrophil count and prognosis. The effects of inflammatory responses mediated by cytokines also influence tumor-associated monocytes, another main regulator of cancer inflammation. Tumor cells induce monocyte differentiation into tumor-associated macrophages, weakening antitumor immune responses and stimulating migration and metastatic spread[23-26]. Peripheral monocyte serum levels are negatively associated with prognosis in different cancer types[27-29].

NLR, LMR, and PLR are inflammatory biomarkers that are independent prognostic factors of survival in several solid tumors, as their assessment is inexpensive[30,31]. Preoperative assessment of the NLR has the clinical potential to predict tumor progression and prognosis in patients with resectable gastric cancer and esophageal squamous cell carcinoma[32,33]. In recent studies, high PLR has been associated with tumor aggressiveness in patients with several malignancies, as well as poor overall survival (OS) and disease-free survival (DFS)[34-38]. Combined NLR and PLR also predicts CT response and prognosis in patients with advanced gastric cancer[39]. Lower LMR is independently associated with worse OS of several malignancies in the advanced setting and more aggressive tumor behavior[40-42]. However, NLR, LMR, and PLR as predictors of response to CT have not been assessed in patients with resectable LAGC cancer.

Tumor regression grade (TRG) is a system used to evaluate residual tumor in patients administered preoperative therapies. TRG focuses on the quantity rather than location of the tumor, providing information on the response to therapies and predicting prognosis[43]. There are many different grading systems without global consensus[44-47]. Among various scores, the College of American Pathology (CAP) TRG score system, based on the relative amount between fibrosis and residual tumor, is widely applied in gastrointestinal cancers[48]. Some studies have suggested that patients with a lower TRG score (1-2 or 1-3) have better survival than those with a higher TRG score (3-5 or 4-5)[44,49,50]. Based on the MAGIC trial, Smyth *et al*[51] found that patients in the TRG 3-5 and node-positive group had worse OS than others, whereas patients with TRG 1-2 and node-negative had better OS.

This goal of this exploratory study was to assess NLR, LMR, and PLR as potential biomarkers for predicting response and survival outcomes in resectable LAGC patients, determined before preoperative CT. To the best of our knowledge, this is the first study to analyze the clinical potential of these ratios in a Portuguese population in a preoperative setting.

**MATERIALS AND METHODS**

***Study design***

This was a multicentric retrospective study including 295 patients from 12 Portuguese oncological centers, diagnosed with resectable LAGC [histologically confirmed advanced clinical stage cT2 or higher, or nodal-positive stage (cN+), or both], who underwent curative intent surgery after at least one preoperative FLOT (preFLOT) cycle, since its initial use in institutions until December 31, 2020. Data collection ended in April 2021, with a minimum follow-up time of 1 mo after surgery.

Participant oncological centers by region were as follows: South & Centre Region - Hospital Professor Doutor Fernando Fonseca, Centro Hospitalar Barreiro-Montijo, Centro Hospitalar Lisboa Ocidental, Centro Hospitalar Lisboa Central, Hospital da Luz de Lisboa, Hospital Beatriz Ângelo, Hospital Garcia de Orta, Hospital Distrital de Santarém, Hospital do Espírito Santo de Évora, Centro Hospitalar Universitário do Algarve; North Region - Centro Hospitalar de Trás-Os-Montes e Alto Douro, and Hospital da Senhora da Oliveira de Guimarães. The exclusion criteria were: Age < 18 years, synchronous or metachronous cancer in other organs, and absence of detailed therapeutic information and unknown laboratory values for NLR, LMR, or PLR.

***Variables***

The database included demographic, histological, clinical, surgical, and pathological variables. Regarding age, patients were divided into elder (≥ 75 years) and non-elder (< 75 years) groups. This division was made due to the growing aging society in western countries, where frailty risk increases above 75 years of age[52]. Neutrophils, lymphocytes, monocytes, and platelets were considered absolute cell counts, based on the last blood sample drawn prior to initiation of preFLOT. NLR was determined by dividing neutrophil absolute count by lymphocyte absolute count, LMR was determined by dividing lymphocyte absolute count by monocyte absolute count, and PLR was determined by dividing platelet absolute count by lymphocyte absolute count[15-20]. Histological diagnosis and grade were considered, as well as tumor site and tumor-node-metastasis (TNM) stage, which was evaluated according to the 8th edition of the American Joint Committee on Cancer staging manual. Patients were staged before the initiation of preoperative therapy. All patients were clinically staged with thorax, abdomen, and pelvic computerized tomography scans; upper endoscopic ultrasound was not requested for additional staging, but if the information was available, it was considered for local staging. Patients were submitted to exploratory laparoscopy for staging purposes, where they were considered for local staging and exclusion of macroscopic peritoneal metastization. Surgical variables included type of resection, type of lymphadenectomy, and margins. Regarding systemic treatment, number of cycles, toxicity, and time until surgery were considered. Pathological tumor response was assessed considering TRG. As previously stated, several grade scoring systems are used, with CAP score being the most used in the participating institutions. To standardize the analysis, we simplified the scores into three categories: Complete tumor regression (pathological complete response), partial/incomplete tumor regression (pathological partial/incomplete response), and no evidence of regression (absence of pathological response). Complete tumor regression was also considered a pathological complete response (pCR). Clinical responses were compared to pathological response obtained with surgery, and tumor downstaging was considered comparing clinical and pathological staging, as at least one of the following: T stage reduction and/or N stage reduction (downstaging). Patients with maintenance or increase in either T or N were considered as not having downstaged. Patients’ period of survival was considered as time since histological diagnosis until death or last time seen alive, in months.

***Statistical analyses***

Data are represented as the relative and absolute frequencies, central tendency measures, and dispersion. Means regarding all ratios were compared using *t*-tests, and in case of non-normality through non-parametric Mann-Whitney tests, specifically for sex, age group (< 75 years *vs* ≥ 75 years), preFLOT suspension, progression under preFLOT, tumor downstaging, T and N regression, TRG, OS and mortality. Analysis of receiver operating characteristics (ROC) curve defined a cut-off value for group stratification, to facilitate patient stratification in the clinical practice. The areas under the curves were calculated to evaluate the predictive abilities of PLR to discriminate patients’ progressive systemic disease and mortality and of LMR to discriminate patients with T downstaging. High PLR was defined as > 141 for progression and > 144 for mortality; high LMR was defined as > 3.56 for T stage regression (TSR). Relative risk was calculated using Poisson regression, with the progression under preFLOT, mortality and TSR the dependent variables and PLR and LMR groups the independent variables. Pearson’s correlation coefficient was used to assess the association between NLR and OS. Kaplan-Meier estimator was used to compare survival curves considering several variables (pCR, TSR, and TRG) and log-rank tests were used to assess statistical significance. Cox regression was used to calculate hazard ratios, with NLR, pCR, TSR, and TRG being the independent variables, and OS the dependent variable. Significance level was established at 0.05. All statistical analyses were performed using SPSS software (version 26.0; IBM Corp. Released 2019. IBM SPSS Statistics for Windows; Armonk, NY, United states). This retrospective observational study was approved on May 19, 2021 by the Ethics Committee of Hospital Professor Doutor Fernando Fonseca (Approval No. 045/2021).

**RESULTS**

Patients’ demographics are described in Table 1. Two-hundred and ninety-five patients were included, with a mean age of 63.7 years (range: 31-84 years), and 59.7% males (*n* = 176). Mostly adenocarcinomas (98.3%), while only 3 patients had non-specified carcinoma and 1 patient had squamous cell carcinoma. Poorly differentiated histology was identified in 40.9% (*n* = 121), while 25.3% (*n* = 75) were moderately differentiated and 8.8% (*n* = 26) well differentiated. Regarding Lauren classification, 51.4% (*n* = 152) were intestinal or mixed subtypes and 20.6% (*n* = 61) were diffuse subtype. Most were located in the stomach (*n* = 272; body: 47%; antrum: 33.8%; cardia: 11.1%), 6.8% (*n* = 20) in the gastroesophageal junction and only 1% (*n* = 3) in the lower esophagus. Peritoneal lavage cytology was performed, prior to therapy initiation, in 253 patients (85.8%), with 42 missing data; of these, 6 patients had a suspicious cytology for neoplastic cells and 3 patients had a positive cytology, but all were considered for surgery in the absence of macroscopic peritoneal metastasis.

Among the 295 patients, the descriptive analysis revealed: Absolute neutrophile counts ranged from 1170 to 21290, with a mean ± SD of 6103 ± 3354; absolute lymphocyte count ranged from 200 to 9110, with a mean ± SD of 1890 ± 1014; absolute monocytes count ranged from 600 to 4440, with a mean ± SD of 585 ± 407; and absolute platelets count ranged from 25600 to 658000, with a mean ± SD of 268658 ± 92373. NLR ranged from 0.48 to 99.5 and mean ± SD was 4.66 ± 7.1; LMR ranged from 0.33 to 143.33 and mean ± SD was 5.29 ± 9.2; and PLR ranged from 15.79 to 1260 and mean ± SD was 182.91 ± 148.19.

Median number of preFLOT cycles was 4 (range: 1-12). Suspension of treatment due to toxicity occurred in 22 patients (7.5%). Twenty-four patients (8.1%) progressed systemically under preFLOT. Median waiting time to surgery was 12 wk (range: 6-33). Regarding patients with curative intent (*n* = 271, 8 missing data): Total gastrectomy was performed in 49% of patients (*n* = 129), while 46% (*n* = 121) had subtotal gastrectomy, 4.1% (*n* = 11) had Ivory-Lewis esophagectomy and 0.8% (*n* = 2) had distal gastrectomy; complete standard lymphadenectomies were performed in 96% (D2: 85.4%, *n* = 193; D1+: 10.6%, *n* = 24), with 45 missing data; R0 resection was achieved in 91.9% patients (*n* = 249), with 9 missing data. TSR occurred in 46.5% (*n* = 126; 17 missing data), and N stage regression occurred in 57.6% (*n* = 156; 9 missing data). Tumor downstaging (TD) defined as TSR and/or N stage regression in comparison of imagiological/clinical *vs* pathological staging, was observed in 61% patients (*n* = 161), while 39% didn’t respond (*n* = 53) or progressed (*n* = 50), with 7 missing data.

Of the 239 surgical specimens evaluated for TRG, using our standardized classification, 46.4% (*n* = 111) showed partial/incomplete response, 33.5% (*n* = 80) no response, and 20.1% (*n* = 48) pCR. Mean OS of general population was 35.1 ± 1.2 mo, with a mean follow-up time of 19.4 ± 0.7 mo. At the end of study time, 233 patients (79%) were alive.

***NLR, LMR, and PLR analyses***

A statistically significant association between NLR and age group (< 75 years *vs* ≥ 75 years) and sex was not found. However, the difference in means was considerable for both variables (NLR mean in male patients = 4.18 *vs* female patients = 5.37, *P* = 0.073; mean in patients ≥ 75 years = 4.21 *vs* patients < 75 years = 4.72, *P* = 0.37) in Table 2. No association was found between NLR and early suspension of treatment due to toxicity. However, difference in means was clinically significant (NLR mean in patients with suspension = 5.32 *vs* without suspension = 4.61; *P* = 0.336). Although TD was not associated with any ratio, difference in means regarding NLR was considerable (mean in patients with TD = 4.93 *vs* without TD = 3.57; *P* = 0.081). NLR was not associated with T or N stage regression, although difference in means was considerable regarding N stage regression (NLR mean in patients with N regression = 5.02 *vs* without N regression = 4.06; *P* = 0.119).

LMR was not associated with sex and age group, but showed a considerable difference between age groups (LMR mean in patients ≥ 75 years = 4.68 *vs* patients < 75 years = 5.37, *P* = 0.335). An association between LMR and TSR was found (*P* = 0.021). Among the 264 patients, LMR ranged from 0.33 to 143.33, with mean ± SD LMR value in patients with T regression (*n* = 126) of 4.38 ± 3.64 and patients without TSR (*n* = 138) of 6.5 ± 12.84. According to ROC analysis, optimal cut-off of LMR was established at 3.56, with a sensitivity/specificity of 0.594 and 0.421. Patients were divided into the following groups according to the cut-off values for LMR: High (> 3.56; *n* = 134) and low LMR (≤ 3.56; *n* = 130). High LMR patients have 1.4-times higher relative risk of achieving TSR than low LMR patients [95% confidence interval (CI): 1.01-1.99; *P* = 0.043] in Table 3.

PLR did not reveal a statistically significant association between sex and age groups, but showed a considerable difference between age groups (PLR mean in patients ≥ 75 years = 214.98 *vs* patients < 75 years = 178.88; *P* = 0.323). Considering early suspension of treatment due to toxicity, PLR did not show to be associated, although difference in means was considerable (PLR mean in patients with suspension = 208.26 *vs* without suspension = 180.87; *P* = 0.144). We also found PLR to be associated with systemic progression during preFLOT (*P* = 0.022). PLR ranged from 15.79 to 1260, with a mean ± SD PLR value in patients with systemic progression during preFLOT (*n* = 24) of 251.94 ± 173.3 and in patients without progression (*n* = 271) of 176.8 ± 144.54. According to ROC analysis, optimal cut-off of PLR was established at 141 for progression, with a sensitivity/specificity for the PLR of 0.667/0.5. Patients were divided into the following groups according to the cut-off values for PLR: High (> 141; *n* = 152) and low PLR (≤ 141; *n* = 143). High PLR patients have 2.2-times higher relative risk of progressing under preFLOT (95%CI: 0.89-5.26; *P* = 0.088).

PLR was not associated with T and/or N stage regression, although difference in means was considerable regarding N stage regression (PLR mean in patients with N regression = 184.45 *vs* without N regression = 166.13; *P* = 0.157). Even though this ratio was not associated with TRG evaluation, difference in means regarding PLR was considerable (PLR mean in patients with partial/incomplete or complete tumor regression to treatment = 180.4 *vs* no evidence of regression to treatment = 189.73; *P* = 0.305). This ratio was also associated with mortality (*P* = 0.013), regardless of surgery. The mean ± SD PLR value in patients dead at the end of the study time analysis (*n* = 62) was 210.27 ± 142.87 and in patients alive at the end of the study time (*n* = 233) was 175.64 ± 149.48. According to ROC analysis, optimal cut-off of PLR was established at 144 for survival status, with a sensitivity/specificity of 0.613/0.481. Patients were divided into the following groups according to the cut-off values for PLR: High (> 144; *n* = 152) and low PLR (≤ 144; *n* = 143). High PLR patients have 1.5 times higher relative risk of dying than low PLR patients, although not statistically significant but the 95%CI lower limit is near 1 (95%CI: 0.92-2.55; *P* = 0.103).

***Survival outcomes***

NLR was found to be associated with OS time, with a weak positive correlation (*r* = 0.143; *P* = 0.014): For every one unit increase in NLR, there was a 0.1 mo increase in mean OS. Nevertheless, through Cox regression, there was no evidence of survival benefit between OS and NLR in Table 3. Neither LMR or PLR were associated with OS. Regarding pCR, the three ratios did not show a statistically significant association nor reveal considerable difference in means. We also did not find an association between pCR and OS; however, difference of means was considerable (mean OS without pCR of 14.9 mo *vs* 18.4 mo with pCR; *P* = 0.428). Although not statistically significant, patients without pCR seem to have higher risk (2.1 times) of dying than patients with pCR (95%CI: 0.8-5.2; *P* = 0.129) in Table 3. With TRG categories as partial/incomplete or complete tumor regression *vs* no evidence of regression to treatment, there was an association with OS (*P* = 0.009), with a survival of 39 mo *vs* 28.5 mo, respectively (95%CI: 33.6-38.4; *P* < 0.001) in Figure 1A. The univariate Cox regression revealed that patients without evidence of tumor regression had 2.8-times higher risk of dying than patients with partial or complete tumor regression (95%CI: 1.6-5, *P* < 0.001). OS was found to be associated with TSR (*P* = 0.03). Patients with T regression had better OS than those without T regression (39.9 mo *vs* 32.7 mo, respectively; *P* = 0.015) in Figure 1B. Univariate Cox regression revealed that patients without TSR had 2.1 times higher risk of dying than patients with TSR (95%CI: 1.14-3.96; *P* = 0.017).

**DISCUSSION**

In summary, our statistically significant results showed that: NLR was weakly (positive) correlated with OS time, but there was no evidence of survival benefit; LMR was associated with TSR; high LMR patients had 1.42-times relative risk of TSR; PLR was associated with systemic progression under preFLOT, as well as mortality; patients without TSR had 2.1-times risk of dying; and patients without pathological tumor regression had 2.8-times higher risk of dying.

Regarding cancer-related mortality and morbidity, gastric cancer is still one of the main causes, despite the development of new approaches, surgery, and systemic treatment-wise[53]. Survival outcomes vary considering patients in different conditions, degrees of invasion and differentiation, as well as TNM stages. The importance of searching for new treatment strategies and their validation, with the objective of improving survival outcomes, relies on the considerable number of patients with advanced disease at diagnosis. The perioperative FLOT strategy, studied by Al-Batran *et al*[3] demonstrated a palpable benefit providing better outcomes. Nonetheless, it is still difficult to predict tumor response to systemic treatment and identify predictive factors to stratify patients into risk groups, which would be important to optimize individualized treatment and follow-up.

Several studies have described a correlation between elevated neutrophil count or high NLR and worse prognosis, as well as progression of disease[39,54]. Our findings seemed to slightly contradict the literature, as we found NLR had a weak positive correlation with OS, revealing that the higher the calculated NLR is, a better OS is expected, but Cox regression did not find an association between NLR and death status. Some studies have published reference values and prognostic correlations for NLR. However, these studies were conducted using small cohort of patients with different races, mainly Asian patients. It is possible differences could be found regarding other populations, specifically European patients. Also, it seems that in the literature there is a consistent difference in sex and age group, which our study supports despite not reaching statistical significance (women and younger patients have a higher NLR mean than men and older patients), but this needs to be replicated in further investigation[55]. This reveals the need for more validation studies in the European population.

LMR has been suggested to be an important factor for predicting prognosis in patients with hematologic and solid malignancies, such as lung and colon cancers[41,42,56-58]. Lower LMR is independently associated with poor OS in gastric cancer patients undergoing radical gastrectomy, and low LMR patients have a higher hazard ratio for both OS and DFS than high LMR[58]. This suggests that lower LMR might be associated with a more aggressive tumor behavior, higher surgical mortality rates, and worse long-term survival[59,60].

Although we did not find evidence of an association between LMR and prognosis, we showed an association between LMR and TSR, with high LMR patients having higher risk of achieving T stage reduction than low LMR patients. Also, our data showed an association between OS and TSR, documenting that patients without TSR had 2.1-times risk of dying, which we could indirectly interpret that patients with high LMR could have a better prognosis. We know that higher TNM staging, specifically T staging, is associated with less survival probability, crosswise solid and hematological tumors, so we could indirectly interpret that patients with low LMR are less likely to have TSR and, consequently, lower survival odds, but this needs to be further investigated.

N stage regression was not found to be associated with the three ratios, but NLR and PLR values seem to be clinically considerable, as patients with N reduction present higher ratio values. Further studies are needed to understand whether advanced TNM staging is associated with higher NLR and PLR ratio values[15,61]. Combining T and N stages to assess TD did not reveal a statistically significant association, despite patients that achieved TD tend to have higher NLR values.

PLR has been widely associated with different stages of tumor development, systemic treatment response and prognostic survival outcomes of cancer patients, namely in LAGC[61-63]. Nonetheless, specific physiopathology is complex and remains unclear. One plausible hypothesis is that a decreased PLR could reflect tumor disadvantage status, such as inflammatory status, immune disorders, malnutrition and thrombosis[64-66]. Low PLR has been associated with less aggressive clinicopathological features, including decreased depth of invasion, less lymph node metastasis, and early tumor stage, while higher risk of lymph node metastasis, increased serosa invasion risk, and advanced stage disease is associated with elevated PLR in patients with gastric cancer[15,61]. It has also been considered a prognostic factor, with high PLR patients being associated with worse OS[39].

Our study found an association between PLR and disease progression during preFLOT, showing that patients with high PLR have higher risk of progressing under CT. We also found a correlation between death and PLR, with high PLR patients having higher risk of dying than low PLR patients. Regarding tumoral response to CT, none of the ratios was associated with pCR achievement, albeit in TRG evaluation, PLR showed a considerable difference in means despite not being statistically significant, with patients without pathological response to CT presenting higher PLR values. Despite not finding an association between pCR and OS, TRG evaluation revealed an association with OS, documenting that patients without pathological tumor regression had 2.8 times higher risk of dying. Although not statistically significant, we could infer that patients with high PLR did not respond so well to CT and could have worse prognosis, despite further analysis is needed. We can extrapolate that these data show a more biologically aggressive tumor and that this might be a reasonable motive for a more active surveillance in these higher risk patients, to detect early progression.

Finally, treatment-associated toxicity is an important clinical factor to be considered in patients, with more emphasis in the elderly population. Although we did not find a correlation between the three ratios and early suspension of treatment due to toxicity, we demonstrate that patients in need of treatment suspension tend to have higher NLR and PLR values. The association with treatment toxicity could be an aspect worthy of future investigation.

This study gathered information suggesting that these biomarkers could be suited to stratify patients by risk to preoperative CT. Knowing the difficulty to predict tumor response before initiation of systemic treatment using clinical and pathological data, we focused on the potential of NLR, LMR and PLR, already reported as systemic inflammatory and immune cancer environment important pieces. Our study stands out from others due to the analysis of these already known blood ratios in a curative setting of gastric cancer, with an approach to the CT response prediction. It has a good representation of Portugal population, being also one of the few studies undergone in a European population: We should keep in mind that possible genetic differences regarding gastric cancer and also inflammation/immune mechanisms should be considered as influencers of the blood ratios analysis (*vs* Asian or Latino-American patients). Due to lack of information regarding treatment prediction in resectable gastric cancer (even less information regarding the European population in this setting), it would be interesting to retrospectively analyze these blood ratios in the phase II/III FLOT4-AIO trial.

The present study had several limitations. First, this exploratory study involved a retrospective analysis in a relatively small population (*n* = 295); consequently, larger validation studies are needed to confirm the potential of these ratios. Second, with NLR, LMR and PLR associated with the inflammatory response, patients under anti-inflammatory effects from other medications could potentially bias the results. Third, we did not control the process and timing of blood collection and analysis; expectedly, blood analysis were undertaken before initiation of systemic treatment, but the period of time since blood results until treatment initiation can widely vary, and patients inflammatory state can be also volatile; depending on the length of time between blood collection and analysis, the composition of blood cells could be altered or destroyed, compromising correct estimation of the different ratios. Fourth, clinical and pathological staging were observational dependent: Every participant hospital was responsible for the evaluation process of its patients, and even different gastroenterologists, radiologists and pathologists evaluated these patients, with possible subjective assessments that could bias the results. Fifth, our median waiting time to surgery was 12 wk, being the recommended interval 4-6 wk (used in the FLOT4-AIO trial); this could possibly be a confounding variable and our results should be replicated prospectively for confirmation.

**CONCLUSION**

We believe that the NLR, LMR, and PLR could be important biomarkers, and that further prospective investigation is needed to validate these ratios and possibly develop a score that could help in the decision-making process in the clinical management of patients with resectable LAGC.

**ARTICLE HIGHLIGHTS**

***Research background***

Fluorouracil plus leucovorin, oxaliplatin, and docetaxel (FLOT) perioperative regimen became the standard of care in resectable locally advanced gastric cancer (LAGC), but there is still a need for prognostic and predictive response biomarkers. Blood ratios, such as neutrophil-to-lymphocyte (NLR), lymphocyte-to-monocyte (LMR) and platelet-to-lymphocyte (PLR) ratios are known prognostic biomarkers in several solid tumors. Tumor regression grade (TRG) is a system used to evaluate residual tumor in patients submitted to preoperative therapies, providing information on the response to therapies and predicting prognosis.

***Research motivation***

This study investigated the prognostic and predictive significance of pre-treatment blood ratios in resectable LAGC.

***Research objectives***

This study assessed the potential value of NLR, LMR, and PLR in predicting survival outcomes and response to preoperative FLOT (preFLOT) regimen in resectable LAGC.

***Research methods***

We retrospectively analyzed patients with resectable LAGC treated with at least one preFLOT cycle, from 12 Portuguese hospitals. NLR, LMR, and PLR pre-treatment values were exploratory correlated with different variables, and with those statistically significant pre-treatment values were divided according to into high or low groups, determined by receiver operating characteristic curve, and evaluated regarding association to survival outcomes and response prediction. Relative risks and hazard ratios were calculated, with NLR, pathological complete response, T stage regression (TSR) and TRG as independent variables, and overall survival (OS) the dependent variable.

***Research results***

We included 295 patients in this study. NLR was correlated with time of survival (*r* = 0.143; *P* = 0.014). High PLR was defined as > 141 for progression and > 144 for mortality; high LMR was defined as > 3.56 for TSR. PLR was associated with systemic progression during FLOT (*P* = 0.022) and mortality (*P* = 0.013), with high PLR patients having 2.2 times higher risk of progression [95% confidence interval (CI): 0.89-5.26] and 1.5 times higher risk of mortality (95%CI: 0.92-2.55). LMR was associated with TSR and high LMR patients have 1.4 times higher risk of achieving TSR (95%CI: 1.01-1.99). OS benefit was found with TSR (*P* = 0.015) and partial/complete TRG (*P* < 0.001). Patients without TSR as well as no evidence of pathological response have 2.1 (95%CI: 1.14-3.96) and 2.8-times (95%CI: 1.6-5) higher risk of death.

***Research conclusions***

NLR, LMR, and PLR are significant biomarkers that are potential indicators for prognosis and treatment response prediction.

***Research perspectives***

In further investigation, validation of these blood ratios is important, as well as integration into risk scores that could help clinicians in the decision-making strategy in the clinical management of patients with resectable LAGC.

**ACKNOWLEDGEMENTS**

We would like to express our gratitude to Dr. Patrícia Soares, from Escola Nacional de Saúde Pública, for all the help and guidance in the statistical analysis of this study.

**REFERENCES**

1 **Global Burden of Disease Cancer Collaboration**, Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, Wolfe C, Hamadeh RR, Moore A, Werdecker A, Gessner BD, Te Ao B, McMahon B, Karimkhani C, Yu C, Cooke GS, Schwebel DC, Carpenter DO, Pereira DM, Nash D, Kazi DS, De Leo D, Plass D, Ukwaja KN, Thurston GD, Yun Jin K, Simard EP, Mills E, Park EK, Catalá-López F, deVeber G, Gotay C, Khan G, Hosgood HD 3rd, Santos IS, Leasher JL, Singh J, Leigh J, Jonas JB, Sanabria J, Beardsley J, Jacobsen KH, Takahashi K, Franklin RC, Ronfani L, Montico M, Naldi L, Tonelli M, Geleijnse J, Petzold M, Shrime MG, Younis M, Yonemoto N, Breitborde N, Yip P, Pourmalek F, Lotufo PA, Esteghamati A, Hankey GJ, Ali R, Lunevicius R, Malekzadeh R, Dellavalle R, Weintraub R, Lucas R, Hay R, Rojas-Rueda D, Westerman R, Sepanlou SG, Nolte S, Patten S, Weichenthal S, Abera SF, Fereshtehnejad SM, Shiue I, Driscoll T, Vasankari T, Alsharif U, Rahimi-Movaghar V, Vlassov VV, Marcenes WS, Mekonnen W, Melaku YA, Yano Y, Artaman A, Campos I, MacLachlan J, Mueller U, Kim D, Trillini M, Eshrati B, Williams HC, Shibuya K, Dandona R, Murthy K, Cowie B, Amare AT, Antonio CA, Castañeda-Orjuela C, van Gool CH, Violante F, Oh IH, Deribe K, Soreide K, Knibbs L, Kereselidze M, Green M, Cardenas R, Roy N, Tillmann T, Li Y, Krueger H, Monasta L, Dey S, Sheikhbahaei S, Hafezi-Nejad N, Kumar GA, Sreeramareddy CT, Dandona L, Wang H, Vollset SE, Mokdad A, Salomon JA, Lozano R, Vos T, Forouzanfar M, Lopez A, Murray C, Naghavi M. The Global Burden of Cancer 2013. *JAMA Oncol* 2015; **1**: 505-527 [PMID: 26181261 DOI: 10.1001/jamaoncol.2015.0735]

2 **Kim SG**, Seo HS, Lee HH, Song KY, Park CH. Comparison of the Differences in Survival Rates between the 7th and 8th Editions of the AJCC TNM Staging System for Gastric Adenocarcinoma: a Single-Institution Study of 5,507 Patients in Korea. *J Gastric Cancer* 2017; **17**: 212-219 [PMID: 28970951 DOI: 10.5230/jgc.2017.17.e23]

3 **Al-Batran SE**, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu FS, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. *Lancet* 2019; **393**: 1948-1957 [PMID: 30982686 DOI: 10.1016/S0140-6736(18)32557-1]

4 **Al-Batran SE**, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J, Schmalenberg H, Luley KB, Prasnikar N, Egger M, Probst S, Messmann H, Moehler M, Fischbach W, Hartmann JT, Mayer F, Höffkes HG, Koenigsmann M, Arnold D, Kraus TW, Grimm K, Berkhoff S, Post S, Jäger E, Bechstein W, Ronellenfitsch U, Mönig S, Hofheinz RD. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. *JAMA Oncol* 2017; **3**: 1237-1244 [PMID: 28448662 DOI: 10.1001/jamaoncol.2017.0515]

5 **Fitzgerald TL**, Efird JT, Bellamy N, Russo SM, Jindal C, Mosquera C, Holliday EG, Biswas T. Perioperative chemotherapy versus postoperative chemoradiotherapy in patients with resectable gastric/gastroesophageal junction adenocarcinomas: A survival analysis of 5058 patients. *Cancer* 2017; **123**: 2909-2917 [PMID: 28386965 DOI: 10.1002/cncr.30692]

6 **Li Y**, Chen J, He Q, Ji X, Wang X, Fan C, Li G. Clinical efficacy of neoadjuvant chemotherapy regimens FLEEOX vs. XELOX in patients with initially unresectable advanced gastric cancer: a propensity score analysis. *Oncotarget* 2017; **8**: 86886-86896 [PMID: 29156843 DOI: 10.18632/oncotarget.19004]

7 **Li Y**, Yang Y, Lu M, Shen L. Predictive value of serum CEA, CA19-9 and CA72.4 in early diagnosis of recurrence after radical resection of gastric cancer. *Hepatogastroenterology* 2011; **58**: 2166-2170 [PMID: 22024091 DOI: 10.5754/hge11753]

8 **Emoto S**, Ishigami H, Yamashita H, Yamaguchi H, Kaisaki S, Kitayama J. Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination. *Gastric Cancer* 2012; **15**: 154-161 [PMID: 21892754 DOI: 10.1007/s10120-011-0091-8]

9 **Wu HH**, Lin WC, Tsai KW. Advances in molecular biomarkers for gastric cancer: miRNAs as emerging novel cancer markers. *Expert Rev Mol Med* 2014; **16**: e1 [PMID: 24456939 DOI: 10.1017/erm.2013.16]

10 **Lauren B**, Ostvar S, Silver E, Ingram M, Oh A, Kumble L, Laszkowska M, Chu JN, Hershman DL, Manji G, Neugut AI, Hur C. Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting. *J Oncol* 2020; **2020**: 2198960 [PMID: 32148492 DOI: 10.1155/2020/2198960]

11 **Hainaut P**, Plymoth A. Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy. *Curr Opin Oncol* 2013; **25**: 50-51 [PMID: 23150341 DOI: 10.1097/CCO.0b013e32835b651e]

12 **Brigati C**, Noonan DM, Albini A, Benelli R. Tumors and inflammatory infiltrates: friends or foes? *Clin Exp Metastasis* 2002; **19**: 247-258 [PMID: 12067205 DOI: 10.1023/a:1015587423262]

13 **Balkwill F**, Mantovani A. Inflammation and cancer: back to Virchow? *Lancet* 2001; **357**: 539-545 [PMID: 11229684 DOI: 10.1016/S0140-6736(00)04046-0]

14 **Coussens LM**, Werb Z. Inflammation and cancer. *Nature* 2002; **420**: 860-867 [PMID: 12490959 DOI: 10.1038/nature01322]

15 **Lian L**, Xia YY, Zhou C, Shen XM, Li XL, Han SG, Zheng Y, Mao ZQ, Gong FR, Wu MY, Chen K, Tao M, Li W. Application of platelet/lymphocyte and neutrophil/lymphocyte ratios in early diagnosis and prognostic prediction in patients with resectable gastric cancer. *Cancer Biomark* 2015; **15**: 899-907 [PMID: 26444485 DOI: 10.3233/CBM-150534]

16 **Wang H**, Ding Y, Li N, Wu L, Gao Y, Xiao C, Jiang H, Zheng Y, Mao C, Deng J, Wang H, Xu N. Prognostic Value of Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio, and Combined Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio in Stage IV Advanced Gastric Cancer. *Front Oncol* 2020; **10**: 841 [PMID: 32637353 DOI: 10.3389/fonc.2020.00841]

17 **Feng JF**, Huang Y, Chen QX. Preoperative platelet lymphocyte ratio (PLR) is superior to neutrophil lymphocyte ratio (NLR) as a predictive factor in patients with esophageal squamous cell carcinoma. *World J Surg Oncol* 2014; **12**: 58 [PMID: 24641770 DOI: 10.1186/1477-7819-12-58]

18 **Hu B**, Yang XR, Xu Y, Sun YF, Sun C, Guo W, Zhang X, Wang WM, Qiu SJ, Zhou J, Fan J. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. *Clin Cancer Res* 2014; **20**: 6212-6222 [PMID: 25271081 DOI: 10.1158/1078-0432.CCR-14-0442]

19 **Hong X**, Cui B, Wang M, Yang Z, Wang L, Xu Q. Systemic Immune-inflammation Index, Based on Platelet Counts and Neutrophil-Lymphocyte Ratio, Is Useful for Predicting Prognosis in Small Cell Lung Cancer. *Tohoku J Exp Med* 2015; **236**: 297-304 [PMID: 26250537 DOI: 10.1620/tjem.236.297]

20 **Liu H**, Wu Y, Wang Z, Yao Y, Chen F, Zhang H, Wang Y, Song Y. Pretreatment platelet-to-lymphocyte ratio (PLR) as a predictor of response to first-line platinum-based chemotherapy and prognosis for patients with non-small cell lung cancer. *J Thorac Dis* 2013; **5**: 783-789 [PMID: 24409356 DOI: 10.3978/j.issn.2072-1439.2013.12.34]

21 **Stanec Z**, Ivrlac R, Hulina D, Dzepina I, Unusić J, Montani D, Prpić I. [An anatomic study of the septofascial layer in the forearm]. *Chir Maxillofac Plast* 1989; **19**: 1-8 [PMID: 2489516 DOI: 10.1007/s12307-014-0147-5]

22 **Ikeguchi M**, Hatada T, Yamamoto M, Miyake T, Matsunaga T, Fukumoto Y, Yamada Y, Fukuda K, Saito H, Tatebe S. Serum interleukin-6 and -10 levels in patients with gastric cancer. *Gastric Cancer* 2009; **12**: 95-100 [PMID: 19562463 DOI: 10.1007/s10120-009-0509-8]

23 **Wilcox RA**, Wada DA, Ziesmer SC, Elsawa SF, Comfere NI, Dietz AB, Novak AJ, Witzig TE, Feldman AL, Pittelkow MR, Ansell SM. Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. *Blood* 2009; **114**: 2936-2944 [PMID: 19671921 DOI: 10.1182/blood-2009-05-220111]

24 **Peng LS**, Zhang JY, Teng YS, Zhao YL, Wang TT, Mao FY, Lv YP, Cheng P, Li WH, Chen N, Duan M, Chen W, Guo G, Zou QM, Zhuang Y. Tumor-Associated Monocytes/Macrophages Impair NK-Cell Function *via* TGFβ1 in Human Gastric Cancer. *Cancer Immunol Res* 2017; **5**: 248-256 [PMID: 28148545 DOI: 10.1158/2326-6066.CIR-16-0152]

25 **Mantovani A**, Schioppa T, Porta C, Allavena P, Sica A. Role of tumor-associated macrophages in tumor progression and invasion. *Cancer Metastasis Rev* 2006; **25**: 315-322 [PMID: 16967326 DOI: 10.1007/s10555-006-9001-7]

26 **Mantovani A**, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. *Nature* 2008; **454**: 436-444 [PMID: 18650914 DOI: 10.1038/nature07205]

27 **Wang YQ**, Zhu YJ, Pan JH, Xu F, Shao XG, Sha JJ, Liu Q, Huang YR, Dong BJ, Xue W. Peripheral monocyte count: an independent diagnostic and prognostic biomarker for prostate cancer - a large Chinese cohort study. *Asian J Androl* 2017; **19**: 579-585 [PMID: 27569002 DOI: 10.4103/1008-682X.186185]

28 **Valero C**, Pardo L, López M, García J, Camacho M, Quer M, León X. Pretreatment count of peripheral neutrophils, monocytes, and lymphocytes as independent prognostic factor in patients with head and neck cancer. *Head Neck* 2017; **39**: 219-226 [PMID: 27534525 DOI: 10.1002/hed.24561]

29 **Han L**, Jia Y, Song Q, Wang N, Wang J, Bai B, Chen X, Wang C, Cheng Y. Prognostic significance of preoperative absolute peripheral monocyte count in esophageal squamous cell carcinoma. *Dis Esophagus* 2016; **29**: 740-746 [PMID: 26316375 DOI: 10.1111/dote.12401]

30 **Diakos CI**, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. *Lancet Oncol* 2014; **15**: e493-e503 [PMID: 25281468 DOI: 10.1016/S1470-2045(14)70263-3]

31 **Roxburgh CS**, McMillan DC. Cancer and systemic inflammation: treat the tumour and treat the host. *Br J Cancer* 2014; **110**: 1409-1412 [PMID: 24548867 DOI: 10.1038/bjc.2014.90]

32 **Arigami T**, Okumura H, Matsumoto M, Uchikado Y, Uenosono Y, Kita Y, Owaki T, Mori S, Kurahara H, Kijima Y, Ishigami S, Natsugoe S. Analysis of the Fibrinogen and Neutrophil-Lymphocyte Ratio in Esophageal Squamous Cell Carcinoma: A Promising Blood Marker of Tumor Progression and Prognosis. *Medicine (Baltimore)* 2015; **94**: e1702 [PMID: 26496280 DOI: 10.1097/MD.0000000000001702]

33 **Arigami T**, Uenosono Y, Matsushita D, Yanagita S, Uchikado Y, Kita Y, Mori S, Kijima Y, Okumura H, Maemura K, Ishigami S, Natsugoe S. Combined fibrinogen concentration and neutrophil-lymphocyte ratio as a prognostic marker of gastric cancer. *Oncol Lett* 2016; **11**: 1537-1544 [PMID: 26893776 DOI: 10.3892/ol.2015.4049]

34 **Kim EY**, Lee JW, Yoo HM, Park CH, Song KY. The Platelet-to-Lymphocyte Ratio Versus Neutrophil-to-Lymphocyte Ratio: Which is Better as a Prognostic Factor in Gastric Cancer? *Ann Surg Oncol* 2015; **22**: 4363-4370 [PMID: 25805235 DOI: 10.1245/s10434-015-4518-z]

35 **Templeton AJ**, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T, Seruga B, Ocaña A, Tannock IF, Amir E. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. *Cancer Epidemiol Biomarkers Prev* 2014; **23**: 1204-1212 [PMID: 24793958 DOI: 10.1158/1055-9965.EPI-14-0146]

36 **Yodying H**, Matsuda A, Miyashita M, Matsumoto S, Sakurazawa N, Yamada M, Uchida E. Prognostic Significance of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Oncologic Outcomes of Esophageal Cancer: A Systematic Review and Meta-analysis. *Ann Surg Oncol* 2016; **23**: 646-654 [PMID: 26416715 DOI: 10.1245/s10434-015-4869-5]

37 **Zhao QT**, Yuan Z, Zhang H, Zhang XP, Wang HE, Wang ZK, Duan GC. Prognostic role of platelet to lymphocyte ratio in non-small cell lung cancers: A meta-analysis including 3,720 patients. *Int J Cancer* 2016; **139**: 164-170 [PMID: 26915723 DOI: 10.1002/ijc.30060]

38 **Lu C**, Gao P, Yang Y, Chen X, Wang L, Yu D, Song Y, Xu Q, Wang Z. Prognostic evaluation of platelet to lymphocyte ratio in patients with colorectal cancer. *Oncotarget* 2017; **8**: 86287-86295 [PMID: 29156795 DOI: 10.18632/oncotarget.21141]

39 **Hirahara T**, Arigami T, Yanagita S, Matsushita D, Uchikado Y, Kita Y, Mori S, Sasaki K, Omoto I, Kurahara H, Maemura K, Okubo K, Uenosono Y, Ishigami S, Natsugoe S. Combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer. *BMC Cancer* 2019; **19**: 672 [PMID: 31286873 DOI: 10.1186/s12885-019-5903-y]

40 **Pan YC**, Jia ZF, Cao DH, Wu YH, Jiang J, Wen SM, Zhao D, Zhang SL, Cao XY. Preoperative lymphocyte-to-monocyte ratio (LMR) could independently predict overall survival of resectable gastric cancer patients. *Medicine (Baltimore)* 2018; **97**: e13896 [PMID: 30593200 DOI: 10.1097/MD.0000000000013896]

41 **Toyokawa T**, Kubo N, Tamura T, Sakurai K, Amano R, Tanaka H, Muguruma K, Yashiro M, Hirakawa K, Ohira M. The pretreatment Controlling Nutritional Status (CONUT) score is an independent prognostic factor in patients with resectable thoracic esophageal squamous cell carcinoma: results from a retrospective study. *BMC Cancer* 2016; **16**: 722 [PMID: 27599460 DOI: 10.1186/s12885-016-2696-0]

42 **Chan JC**, Chan DL, Diakos CI, Engel A, Pavlakis N, Gill A, Clarke SJ. The Lymphocyte-to-Monocyte Ratio is a Superior Predictor of Overall Survival in Comparison to Established Biomarkers of Resectable Colorectal Cancer. *Ann Surg* 2017; **265**: 539-546 [PMID: 27070934 DOI: 10.1097/SLA.0000000000001743]

43 **Davies AR**, Gossage JA, Zylstra J, Mattsson F, Lagergren J, Maisey N, Smyth EC, Cunningham D, Allum WH, Mason RC. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction. *J Clin Oncol* 2014; **32**: 2983-2990 [PMID: 25071104 DOI: 10.1200/JCO.2014.55.9070]

44 **Mandard AM**, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. *Cancer* 1994; **73**: 2680-2686 [PMID: 8194005 DOI: 10.1002/1097-0142(19940601)73:11<2680::aid-cncr2820731105>3.0.co;2-c]

45 **Ryan R**, Gibbons D, Hyland JM, Treanor D, White A, Mulcahy HE, O'Donoghue DP, Moriarty M, Fennelly D, Sheahan K. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. *Histopathology* 2005; **47**: 141-146 [PMID: 16045774 DOI: 10.1111/j.1365-2559.2005.02176.x]

46 **Becker K**, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, Böttcher K, Siewert JR, Höfler H. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. *Cancer* 2003; **98**: 1521-1530 [PMID: 14508841 DOI: 10.1002/cncr.11660]

47 **Rödel C**, Martus P, Papadoupolos T, Füzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, Wittekind C. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. *J Clin Oncol* 2005; **23**: 8688-8696 [PMID: 16246976 DOI: 10.1200/JCO.2005.02.1329]

48 **Burgart LJ**, Chopp WV, Jain D. Protocol for the Examination of Specimens From Patients With Carcinoma of the Stomach. College of American Pathologists, 2021

49 **Noble F**, Lloyd MA, Turkington R, Griffiths E, O'Donovan M, O'Neill JR, Mercer S, Parsons SL, Fitzgerald RC, Underwood TJ; OCCAMS consortium. Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma. *Br J Surg* 2017; **104**: 1816-1828 [PMID: 28944954 DOI: 10.1002/bjs.10627]

50 **Mokadem I**, Dijksterhuis WPM, van Putten M, Heuthorst L, de Vos-Geelen JM, Haj Mohammad N, Nieuwenhuijzen GAP, van Laarhoven HWM, Verhoeven RHA. Recurrence after preoperative chemotherapy and surgery for gastric adenocarcinoma: a multicenter study. *Gastric Cancer* 2019; **22**: 1263-1273 [PMID: 30949777 DOI: 10.1007/s10120-019-00956-6]

51 **Smyth EC**, Fassan M, Cunningham D, Allum WH, Okines AF, Lampis A, Hahne JC, Rugge M, Peckitt C, Nankivell M, Langley R, Ghidini M, Braconi C, Wotherspoon A, Grabsch HI, Valeri N. Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial. *J Clin Oncol* 2016; **34**: 2721-2727 [PMID: 27298411 DOI: 10.1200/JCO.2015.65.7692]

52 **Torpy JM**, Lynm C, Glass RM. JAMA patient page. Frailty in older adults. *JAMA* 2006; **296**: 2280 [PMID: 17090776 DOI: 10.1001/jama.296.18.2280]

53 **Miller KD**, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL, Siegel RL. Cancer treatment and survivorship statistics, 2019. *CA Cancer J Clin* 2019; **69**: 363-385 [PMID: 31184787 DOI: 10.3322/caac.21565]

54 **Murakami Y**, Saito H, Shimizu S, Kono Y, Shishido Y, Miyatani K, Matsunaga T, Fukumoto Y, Fujiwara Y. Neutrophil-to-Lymphocyte Ratio as a Prognostic Indicator in Patients With Unresectable Gastric Cancer. *Anticancer Res* 2019; **39**: 2583-2589 [PMID: 31092456 DOI: 10.21873/anticanres.13381]

55 **Lee JS**, Kim NY, Na SH, Youn YH, Shin CS. Reference values of neutrophil-lymphocyte ratio, lymphocyte-monocyte ratio, platelet-lymphocyte ratio, and mean platelet volume in healthy adults in South Korea. *Medicine (Baltimore)* 2018; **97**: e11138 [PMID: 29952958 DOI: 10.1097/MD.0000000000011138]

56 **Hu P**, Shen H, Wang G, Zhang P, Liu Q, Du J. Prognostic significance of systemic inflammation-based lymphocyte- monocyte ratio in patients with lung cancer: based on a large cohort study. *PLoS One* 2014; **9**: e108062 [PMID: 25275631 DOI: 10.1371/journal.pone.0108062]

57 **Stotz M**, Pichler M, Absenger G, Szkandera J, Arminger F, Schaberl-Moser R, Samonigg H, Stojakovic T, Gerger A. The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. *Br J Cancer* 2014; **110**: 435-440 [PMID: 24357796 DOI: 10.1038/bjc.2013.785]

58 **Lieto E**, Galizia G, Auricchio A, Cardella F, Mabilia A, Basile N, Del Sorbo G, Castellano P, Romano C, Orditura M, Napolitano V. Preoperative Neutrophil to Lymphocyte Ratio and Lymphocyte to Monocyte Ratio are Prognostic Factors in Gastric Cancers Undergoing Surgery. *J Gastrointest Surg* 2017; **21**: 1764-1774 [PMID: 28752404 DOI: 10.1007/s11605-017-3515-x]

59 **Hsu JT**, Wang CC, Le PH, Chen TH, Kuo CJ, Lin CJ, Chou WC, Yeh TS. Lymphocyte-to-monocyte ratios predict gastric cancer surgical outcomes. *J Surg Res* 2016; **202**: 284-290 [PMID: 27229102 DOI: 10.1016/j.jss.2016.01.005]

60 **Cong X**, Li S, Xue Y. [Impact of preoperative lymphocyte to monocyte ratio on the prognosis of the elderly patients with stage II(-III( gastric cancer]. *Zhonghua Wei Chang Wai Ke Za Zhi* 2016; **19**: 1144-1148 [PMID: 27781252]

61 **Zhang X**, Zhao W, Yu Y, Qi X, Song L, Zhang C, Li G, Yang L. Clinicopathological and prognostic significance of platelet-lymphocyte ratio (PLR) in gastric cancer: an updated meta-analysis. *World J Surg Oncol* 2020; **18**: 191 [PMID: 32731872 DOI: 10.1186/s12957-020-01952-2]

62 **Zhou X**, Xu L, Huang Z, Zhang L, Zhang H, Zhu W, Liu P. The hematologic markers as prognostic factors in patients with resectable gastric cancer. *Cancer Biomark* 2016; **17**: 359-367 [PMID: 27434296 DOI: 10.3233/CBM-160648]

63 **Deng J**, Zhang P, Sun Y, Peng P, Huang Y. Prognostic and clinicopathological significance of platelet to lymphocyte ratio in esophageal cancer: a meta-analysis. *J Thorac Dis* 2018; **10**: 1522-1531 [PMID: 29707302 DOI: 10.21037/jtd.2018.02.58]

64 **Cruz-Ramos M**, Del Puerto-Nevado L, Zheng B, López-Bajo R, Cebrian A, Rodríguez-Remirez M, García-García L, Solanes-Casado S, García-Foncillas J. Prognostic significance of neutrophil-to lymphocyte ratio and platelet-to lymphocyte ratio in older patients with metastatic colorectal cancer. *J Geriatr Oncol* 2019; **10**: 742-748 [PMID: 30327283 DOI: 10.1016/j.jgo.2018.10.002]

65 **Pang W**, Lou N, Jin C, Hu C, Arvine C, Zhu G, Shen X. Combination of preoperative platelet/lymphocyte and neutrophil/lymphocyte rates and tumor-related factors to predict lymph node metastasis in patients with gastric cancer. *Eur J Gastroenterol Hepatol* 2016; **28**: 493-502 [PMID: 26854795 DOI: 10.1097/MEG.0000000000000563]

66 **Moyes LH**, Leitch EF, McKee RF, Anderson JH, Horgan PG, McMillan DC. Preoperative systemic inflammation predicts postoperative infectious complications in patients undergoing curative resection for colorectal cancer. *Br J Cancer* 2009; **100**: 1236-1239 [PMID: 19319134 DOI: 10.1038/sj.bjc.6604997]

**Footnotes**

**Institutional review board statement:** The study was reviewed and approved by the Ethical Committee for Health of Hospital Professor Doutor Fernando Fonseca (approval No. 045/2021).

**Informed consent statement:** The informed consent statement was waived.

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Data sharing statement:** No data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** August 2, 2021

**First decision:** September 5, 2021

**Article in press:** June 23, 2022

**Specialty type:** Oncology

**Country/Territory of origin:** Portugal

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0


Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** An T, China **S-Editor:** Wang JJ **L-Editor:** Filipodia **P-Editor:** Wang JJ

**Figure Legends**



**Figure 1 Overall Survival curves of resectable locally advanced gastroesophageal cancer patients.** A: Stratified by tumor regression grade status, a: Partial/incomplete or complete tumor regression; b: No evidence of regression; B: Stratified by pathological T stage regression status, a: T stage regression; b: T stage persistence or progression. OS: Overall survival; TRG: Tumor regression grade; CI: Confidence interval.

**Table 1 Patients’ demographics**

|  |  |
| --- | --- |
|  | **All, *n* = 295** |
| Age at diagnosis in yr, mean (min-max) | 63.7 (31-84) |
| Male, *n* (%) | 176 (59.7%) |
| Primary tumor site, *n* (%) |  |
| Stomach |  |
| Body | 139 (47.1%) |
| Antrum | 100 (33.9%) |
| Cardia | 33 (11.2%) |
| Lower esophagus | 3 (1%) |
| Gastroesophageal junction | 20 (6.8%) |
| Lauren classification1, *n* (%) |  |
| Diffuse | 61 (21.6%) |
| Intestinal or mixed | 152 (53.9%) |
| NOS | 69 (24.5%) |
| Differentiation degree2, *n* (%) |  |
| Well differentiated | 26 (11.7%) |
| Moderately differentiated | 75 (33.8%) |
| Poorly differentiated | 121 (54.5%) |
| Blood cell count and blood ratios serum quantification, mean ± SD |  |
| Neutrophiles | 6103 ± 3354 |
| Lymphocytes | 1890 ± 1014 |
| Platelets | 268658 ± 92373 |
| Monocytes | 585 ± 407 |
| NLR | 4.66 ± 7.1 |
| LMR | 5.29 ± 9.2 |
| PLR | 182.91 ± 148.19 |
| Clinical/imagiological T stage3, *n* (%) |  |
| T1 | 12 (4.3%) |
| T2 | 67 (23.8%) |
| T3 | 130 (46.3%) |
| T4 | 72 (25.6%) |
| Clinical/imagiological N stage4, *n* (%) |  |
| Nx | 14 (4.8%) |
| N0 | 43 (14.7%) |
| N1 | 66 (22.5%) |
| N2 | 62 (21.2%) |
| N3 | 7 (2.4%) |
| N+ | 101 34.5%) |
| PreFLOT cycles, median (min-max) | 4 (1-12) |
| Progressive disease under preFLOT, *n* (%) | 24 (8.1%) |
| Suspension of preFLOT due to toxicity, *n* (%) | 22 (7.5%) |
| Waiting time to surgery in wk, median (min-max) | 12 (6-33) |
| Patients submitted to surgery5, *n* (%) | 271 (91.9%) |
| Total gastrectomy | 129 (49%) |
| Subtotal gastrectomy | 121 (46%) |
| Distal gastrectomy | 2 (0.8%) |
| Esophagectomy | 11 (4.1%) |
| Lymphadenectomy6, *n* (%) |  |
| D1 | 9 (4%) |
| D1+ | 24 (10.6%) |
| D2 | 193 (85.4%) |
| Resection margin7, *n* (%) |  |
| 0 | 249 (95%) |
| 1 | 13 (5%) |
| Pathological T stage4, *n* (%) |  |
| T0 | 40 (14.7%) |
| Tis | 2 (0.7%) |
| T1 | 52 (19%) |
| T2 | 39 (14.3%) |
| T3 | 96 (35.2%) |
| T4 | 44 (16.1%) |
| Pathological N stage4, *n* (%) |  |
| N0 | 147 (53.8%) |
| N1 | 36 (13.2) |
| N2 | 48 (17.6%) |
| N3 | 42 (15.4%) |
| Pathological stage regression, *n* (%) |  |
| T stage regression8 | 126 (46.5%) |
| N stage regression9 | 156 (57.6%) |
| Post-surgery tumor staging status, *n* (%) |  |
| Tumor downstaging | 161 (61%) |
| No response | 53 (20.1%) |
| Tumor upstaging | 50 (18.9%) |
| TRG10, *n* (%) |  |
| Complete tumor regression | 48 (20.1%) |
| Partial/incomplete tumor regression | 111 (46.4%) |
| No evidence of regression | 80 (33.5%) |
| Mortality status at the end of study time, *n* (%) |  |
| Dead | 62 (21%) |
| Alive | 233 (79%) |

113 missing data.

273 missing data.

314 missing data.

422 missing data.

58 missing data.

645 missing data.

79 missing data.

817 missing data.

99 missing data.

1056 missing data.

FLOT: Fluorouracil plus leucovorin, oxaliplatin, and docetaxel; LMR: Lymphocyte-to-monocyte ratio; NLR: Neutrophile-to-lymphocyte ratio; NOS: Nitric oxide synthase; PLR: Platelet-to-lymphocyte ratio; preFLOT: Preoperative fluorouracil plus leucovorin, oxaliplatin, and docetaxel; SD: Standard deviation; TRG: Tumor regression grade.

**Table 2 Relationship between neutrophil-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios and clinicopathological variables in patients with resectable locally advanced gastroesophageal cancer**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **NLR, mean ± SD** | ***P* value** | **LMR, mean ± SD** | ***P* value** | **PLR, mean ± SD** | ***P* value** |
| Age |  | 0.37 |  | 0.323 |  | 0.335 |
| < 75 yr (*n* = 262) | 4.72 ± 7.24 |  | 5.37 ± 9.66 |  | 178.88 ± 129.45 |  |
| ≥ 75 yr (*n* = 33) | 4.21 ± 5.94 |  | 4.69 ± 4.06 |  | 214.98 ± 252.77 |  |
| Sex |  | 0.073 |  | 0.435 |  | 0.177 |
| Male (*n* = 176) | 4.19 ± 4.33 |  | 5.12 ± 4.9 |  | 169.61 ± 120.07 |  |
| Female (*n* = 119) | 5.37 ± 9.84 |  | 5.55 ± 13.24 |  | 202.6 ± 146.38 |  |
| Treatment suspension due to toxicity |  | 0.336 |  | 0.818 |  | 0.144 |
| Yes (*n* = 22) | 5.32 ± 5.5 |  | 5.05 ± 3.89 |  | 208.26 ± 136.91 |  |
| No (*n* = 273) | 4.61 ± 7.22 |  | 5.31 ± 9.5 |  | 180.87 ± 149.11 |  |
| Systemic progression under preFLOT |  | 0.935 |  | 0.287 |  | 0.022 |
| Yes (*n* = 24) | 4.66 ± 4.48 |  | 3.78 ± 2.9 |  | 251.94 ± 173.3 |  |
| No (*n* = 271) | 4.66 ± 7.29 |  | 5.43 ± 9.55 |  | 176.8 ± 144.54 |  |
| T stage regression |  | 0.743 |  | 0.021 |  | 0.62 |
| Yes (*n* = 126) | 4.14 ± 3.94 |  | 4.38 ± 3.64 |  | 168.23 ± 117.2 |  |
| No (*n* = 138) | 4.73 ± 8.97 |  | 6.5 ± 12.84 |  | 177.73 ± 145.62 |  |
| N stage regression |  | 0.119 |  | 0.635 |  | 0.157 |
| Yes (*n* = 156) | 5.04 ± 8.81 |  | 5.76 ± 12.04 |  | 184.45 ± 140.76 |  |
| No (*n* = 115) | 4.06 ± 4.56 |  | 4.91 ± 4.29 |  | 166.13 ± 150.31 |  |
| Tumor downstaging |  | 0.081 |  | 0.873 |  | 0.82 |
| Yes (*n* = 161) | 5.07 ± 8.58 |  | 4.7 ± 4.27 |  | 180.13 ± 139.93 |  |
| No (*n* = 103) | 4.02 ± 4.74 |  | 6.58 ± 14.42 |  | 197.79 ± 154.23 |  |
| TRG |  | 0.9 |  | 0.99 |  | 0.305 |
| Partial/incomplete or complete regression (*n* = 161) | 4.87 ± 8.45 |  | 5.17 ± 11.49 |  | 180.4 ± 139.45 |  |
| No evidence of regression (*n* = 86) | 4.77 ± 5.3 |  | 4.45 ± 3.63 |  | 189.73 ± 157.16 |  |
| Pathological complete response |  | 0.511 |  | 0.472 |  | 0.832 |
| Yes (*n* = 48) | 4.32 ± 3.73 |  | 4.62 ± 4.1 |  | 177 ± 138.81 |  |
| No (*n* = 191) | 5 ± 8.23 |  | 5.09 ± 10.54 |  | 183.87 ± 151.46 |  |
| Mortality status at the end of study time |  | 0.082 |  | 0.14 |  | 0.013 |
| Alive (*n* = 233) | 4.47 ± 7.45 |  | 5.6 ± 10.18 |  | 175.64 ± 149.02 |  |
| Dead (*n* = 62) | 5.38 ± 5.57 |  | 4.15 ± 3.45 |  | 210.27 ± 142.87 |  |

FLOT: Fluorouracil plus leucovorin, oxaliplatin, and docetaxel; LMR: Lymphocyte-to-monocyte ratio; NLR: Neutrophile-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; preFLOT: Preoperative fluorouracil plus leucovorin, oxaliplatin, and docetaxel; SD: Standard deviation; TRG: Tumor regression grade.

**Table 3 Univariate regressions of significant predictive or prognostic factors in resectable locally advanced gastroesophageal cancer patients**

|  |  |  |  |
| --- | --- | --- | --- |
| **Poisson regression** | **Relative risk (95%CI)** | **Hazard ratio (95%CI)** | ***P* value** |
| T stage regression between LMR groups |  |  |  |
| > 3.56/≤ 3.56 | 1.42 (1.01-1.99) |  | 0.043 |
| Progression between PLR groups |  |  |  |
| > 141/≤ 141 | 2.17 (0.89-5.26) |  | 0.088 |
| Mortality between PLR groups |  |  |  |
| > 144/≤ 144 | 1.53 (0.92-2.55) |  | 0.103 |
| Cox regression |  |  |  |
| NLR |  | 1 (0.97-1.0) | 0.972 |
| Patients without pCR |  | 2.1 (0.8-5.2) | 0.129 |
| Patients without (pathological) tumor regression |  | 2.8 (1.6-5) | < 0.001 |
| Patients without T stage regression |  | 2.1 (1.1-3.9) | 0.017 |

CI: Confidence interval; FLOT: Fluorouracil plus leucovorin, oxaliplatin, and docetaxel; LMR: Lymphocyte-to-monocyte ratio; NLR: Neutrophile-to-lymphocyte ratio; pCR: Pathological complete response; PLR: Platelet-to-lymphocyte ratio; preFLOT: Preoperative fluorouracil plus leucovorin, oxaliplatin, and docetaxel; TRG: Tumor regression grade.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**